Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALACRITY: AZD0120 in Relapsed or Refractory AL Amyloidosis
NCT07081646Phase 2Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Aug 2029
- Modality
- CAR-T Cells
- Countries
- 3
01
Overview
A Phase 2 trial of GC012 in light-chain amyloidosis, sponsored by Alexion Pharmaceuticals. Started Aug 2025; status: recruiting.
02
Drugs
GC012
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT07081646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081646.